Pre-release: this release has not been published. Identifiers are permanent; descriptions may still change.
21 CFR 312.84 Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and severely-debilitating illnesses.
21 CFR 312.84 Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and severely-debilitating illnesses., “Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and…”, is a CFR section of 21 CFR Part 312, Subpart E—Drugs Intended to Treat Life-threatening and Severely-debilitating Illnesses; in force.
https://ontology.bommaritollc.com/id/01a0f094-c4ad-70e9-8fec-e2b1899763eb
Elsewhere
Facts
| adms:identifier | |
| eli:cites | |
| prov:wasDerivedFrom | |
| schema:isPartOf | |
| schema:legislationIdentifier | 21 CFR 312.84 |
| schema:legislationJurisdiction | |
| schema:legislationLegalForce | |
| schema:legislationType | |
| schema:name | Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and severely-debilitating illnessesen |
| schema:url | |
| skos:prefLabel | 21 CFR 312.84 Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and severely-debilitating illnesses.en |